Form 4: Procept BioRobotics CEO Reza Zadno Sells Shares Under 10b5-1 Trading Plan

Procept BioRobotics CEO Reza Zadno sold a total of 26,420 shares of common stock on November 27, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Reza Zadno, CEO of Procept BioRobotics, sold 26,420 shares of common stock on November 27, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2024.
• The shares were sold in multiple transactions at varying weighted average prices.
• The prices ranged from $96.74 to $100.14 per share.
• Following the transactions, Mr. Zadno directly owns 179,185 shares of Procept BioRobotics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-arranged trading plan, which is neither particularly positive nor negative. It's a neutral event from an investment perspective.

Risks

• Sales by company executives can sometimes be perceived negatively by the market, potentially impacting the stock price.

Industry Context

Insider trading activity is a common occurrence in publicly traded companies, and the use of 10b5-1 plans is a standard practice for executives to manage their stock sales while avoiding accusations of trading on non-public information.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the medical device industry like Procept BioRobotics.
• Similar filings are regularly seen from executives at companies such as Intuitive Surgical (ISRG) and Stryker (SYK), indicating that this type of transaction is a normal part of executive compensation and financial planning.

Stakeholder Impact

• The stock sale may have a minor impact on shareholder sentiment, but it is unlikely to be significant given the pre-planned nature of the transaction.

Key Dates

Keywords

insider trading, Form 4, stock sale, Rule 10b5-1, Procept BioRobotics, Reza Zadno, executive